港股市场今日上午，生物制药公司荣昌生物（09995.HK）股价表现强劲，盘中大涨9.09%，引发市场关注。截至上午10点43分，该股报价95.95港元，成交额达3.83亿港元。
荣昌生物近期发布的2025年上半年业绩报告显示，公司营收同比增长48%至10.9亿元，归母净亏损同比大幅收窄3.3亿元至4.5亿元。业绩改善主要得益于公司核心产品泰它西普和维迪西妥单抗的销量持续增加。值得注意的是，这两款产品均于2021年进入医保目录，为销售增长提供了有力支撑。
分析师对荣昌生物的前景持乐观态度。中金指出，公司核心产品适应症的不断拓展将推动商业化持续加速。目前，泰它西普用于治疗重症肌无力（gMG）已获批上市，预计在2025年下半年还将为系统性硬化症（pSS）和IgA肾病（IgAN）递交上市申请。此外，维迪西妥单抗在乳腺癌和尿路上皮癌等领域的适应症拓展也在稳步推进。这些因素综合推动了投资者信心，促使荣昌生物股价在今日交易中显著上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.